Trial Profile
An Open Label, Single-Centre, Phase II Study for Radiosensitization of Everolimus With External Beam Radiotherapy for the Treatment of Metastatic Neuroendocrine Liver Metastasis
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 22 Aug 2022
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Liver metastases; Neuroendocrine tumours
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Acronyms EBRT
- 17 Aug 2022 Status changed from recruiting to completed.
- 22 Jul 2016 Status changed from not yet recruiting to recruiting.
- 29 Feb 2016 Planned number of patients changed from 10 to 14 as reported by ClinicalTrials.gov record.